NCT00038948

Study Comparing Conversion to Sirolimus vs. Continued Use of Calcineurin Inhibitors in Kidney Transplant Recipients

A Randomized, Open-label, Comparative Evaluation of Conversion From Calcineurin Inhibitors to Sirolimus Versus Continued Use of Calcineurin Inhibitors in Renal Allograft Recipients

• Status: Completed
• Phase: Phase 3
• Study type: Interventional
• Enrollment: 830 (actual)
• Sponsor: Wyeth is now a wholly owned subsidiary of Pfizer · Industry
• Sex: All
• Age: 13 Years
• Healthy volunteers: Not accepted

Summary

The purpose of this study is to determine the effect of conversion from calcineurin inhibitor to sirolimus based therapy on renal function.

Conditions

• Renal Transplantation

Interventions

Type	Name	Description
DRUG	Sirolimus	Sirolimus, Cyclosporine A \& Tacrolimus are concentration controlled
DRUG	tacrolimus
DRUG	Cyclosporine A

Timeline

• Start date: 2002-01-01
• Primary completion: 2008-05-01
• Completion: 2008-05-01
• First posted: 2002-06-07
• Last updated: 2010-05-14
• Results posted: 2010-05-14